Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Black Diamond Therapeutics, Inc. (BDTX) had Stock-Based Compensation of $6.63M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-15.12M |
|
-- |
|
-- |
|
$17.61M |
|
$-17.61M |
|
$2.49M |
|
$-15.12M |
|
$-15.12M |
|
$-15.12M |
|
$-15.12M |
|
$-15.12M |
|
$-15.12M |
|
$-17.61M |
|
$-17.54M |
|
56.87M |
|
57.56M |
|
$-0.27 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$132.44M |
|
$0.36M |
|
$10.57M |
|
$143.01M |
|
$15.73M |
|
-- |
|
$15.07M |
|
$30.80M |
|
$112.21M |
|
$112.21M |
|
$112.21M |
|
57.14M |
|
| Cash Flow Statement Financials | |
$29.61M |
|
$-44.91M |
|
$-0.15M |
|
$37.26M |
|
$21.82M |
|
$-15.44M |
|
|
Stock-Based Compensation |
$6.63M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$29.64M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.47% |
|
-13.47% |
|
-10.57% |
|
-13.47% |
|
$1.96 |
|
$0.51 |
|
$0.51 |
|